MedImmune: Vaccine ready to go at month's end

MedImmune, which began clinical trials for its swine flu vaccine last month, says the inhaled vaccine could be ready by the end of September. The AstraZeneca subsidiary is now waiting on the FDA to review its safety data. "There are no red flags there," Dr. Raburn Mallory told Reuters. "We think we can have 5 million doses ready to distribute at the end of September." Once it gets the greenlight, MedImmune says it will begin shipping the nasal spray vaccine to the U.S. government to fulfill its $90 million contract. Article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.